{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:03:44Z","timestamp":1782417824898,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Tandem stem cell transplantation (<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) is an option for high\u2010risk relapsed\/refractory Hodgkin Lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) patients. We evaluated the tolerance\/efficacy of double autologous or autologous <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>) followed by allogenic <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> (allo<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) in 120 <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients prospectively registered on a French nationwide database. Median age was 26 (14\u201356)\u00a0years. Complete remission rate was 60%, including 33% after a single line, and another 27% after two or more salvage regimens. Partial response rate was 32%, and 8% suffered treatment failure. Overall, 115 (96%) patients underwent a first <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>, and 73 (61%) had a tandem <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>, including allo<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> in 44 (60%) and <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content> in 29 (40%). The median follow\u2010up was 43\u00a0months (4.8\u201373.7\u00a0months). The two\u2010year progression\u2010free survival rate for the whole population and for patients receiving tandem transplant was 56% (95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>]: 46\u201365%) and 71% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 49\u201384%), respectively. Among tandem transplants, we observed 20 deaths (17%), 10 of which were transplant\u2010related (6 allo<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> and 4 <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>). We suggest that tandem <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> is efficient in high\u2010risk relapsed\/refractory <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients, although transplant\u2010related mortality remains high. The benefit of tandem <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> should be balanced with the efficacy of Brentuximab vedotin\u2010based post\u2010transplant consolidative strategies in high\u2010risk relapsed\/refractory <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients.<\/jats:p>","DOI":"10.1111\/bjh.15184","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T05:02:37Z","timestamp":1522731757000},"page":"341-349","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tandem haematopoietic stem cell transplantation for High Risk relapsed\/refractory Hodgkin Lymphoma: a <scp>LYSA<\/scp> study"],"prefix":"10.1111","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-5466","authenticated-orcid":false,"given":"Benedicte","family":"Deau","sequence":"first","affiliation":[{"name":"Hopital Cochin Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Amorim","sequence":"additional","affiliation":[{"name":"Hopital Saint Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"CHU Nancy Vandroeuvre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Quittet","sequence":"additional","affiliation":[{"name":"CHU Montpellier Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Cornillon","sequence":"additional","affiliation":[{"name":"Institut Cancerologique de la Loire St\u2010Priest en Jarez France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Driss","family":"Chaoui","sequence":"additional","affiliation":[{"name":"CH Argenteuil Argenteuil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean P.","family":"Marolleau","sequence":"additional","affiliation":[{"name":"CH Amiens Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[{"name":"CHU Toulouse Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katell","family":"Le Du","sequence":"additional","affiliation":[{"name":"Clinique Victor Hugo Le Mans Le Mans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u2010Matthieu","family":"Fornecker","sequence":"additional","affiliation":[{"name":"CHU Strasbourg Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"CHU Clermont Ferrand Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Veillard","sequence":"additional","affiliation":[{"name":"Lymphoma Academic Research Organisation (LYSARC) Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Chaillol","sequence":"additional","affiliation":[{"name":"Lymphoma Academic Research Organisation (LYSARC) Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[{"name":"Hopital Saint Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Tamburini","sequence":"additional","affiliation":[{"name":"Hopital Cochin Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[{"name":"Hopital Saint Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.222"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.113571"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008343823292"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx072"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.23.3918"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20790"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056051"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000067"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701981"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.01.072"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1280"},{"key":"e_1_2_7_15_1","article-title":"Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma","author":"Kalac M.","year":"2016","journal-title":"British Journal of Haematology"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903040048"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124784"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5887"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388058"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.177"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136408"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.1386"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.798"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi119"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2415"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.045757"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15184","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:52:18Z","timestamp":1695570738000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/bjh.15184"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15184","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,2]]},"assertion":[{"value":"2017-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}